
    
      One hundred and sixty eight patients will be randomly assigned to one of four investigational
      treatment regimens in this outpatient study. For active treatment arms, study drug will be
      titrated to the assigned dosage and then maintained for up to a 12 week follow-up period
      before receiving tapered doses in advance of study completion. Dosing will take place over a
      total of about 13 weeks.
    
  